

Antonio D Avolio

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3027989/antonio-davolio-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

300
papers

4,622
citations

34
h-index

50
g-index

317
ext. papers

5,331
ext. citations

4.7
avg, IF

5.5
L-index

#	Paper	IF	Citations
300	25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. <i>Nutrients</i> , 2020 , 12,	6.7	236
299	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010 , 24, 1064-6	3.5	103
298	An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 662-9	3.2	99
297	A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 125, 369-75	3.5	96
296	New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 1721-6	3.2	82
295	HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 859, 234-40	3.2	77
294	In vitro activity of propolis against <i>Streptococcus pyogenes</i> . <i>Letters in Applied Microbiology</i> , 2000 , 31, 174-7	2.9	76
293	Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1222-5	11.6	73
292	Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 396, 791-8	4.4	64
291	Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5242-50	5.9	63
290	HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010 , 52, 774-80	3.5	62
289	Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. <i>BMC Cancer</i> , 2014 , 14, 184	4.8	61
288	Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 3966 ⁵⁹	5.9	60
287	Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2977-2980	5.1	55
286	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 54, 779-88	3.5	55
285	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 59, 109-16	3.5	53
284	Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2976-8	5.9	53

283	Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 590-6	3.1	50
282	The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 919-24	5.1	47
281	LC-MS application for therapeutic drug monitoring in alternative matrices. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 166, 40-51	3.5	47
280	Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 835, 127-30	3.2	46
279	Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect. <i>Bioanalysis</i> , 2017 , 9, 1093-1105	2.1	45
278	Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3408-13	5.9	45
277	Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 224, 391.e1-391.e7	6.4	45
276	A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?. <i>Current Drug Metabolism</i> , 2014 , 15, 581-98	3.5	43
275	Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. <i>Clinical Infectious Diseases</i> , 2015 , 60, 311-7	11.6	41
274	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1772-1777	5.1	41
273	Cannabinoids concentration variability in cannabis olive oil galenic preparations. <i>Journal of Pharmacy and Pharmacology</i> , 2018 , 70, 143-149	4.8	40
272	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 759-65	1.9	38
271	Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 165-70	3.2	37
270	Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 104-9	3.2	36
269	A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. <i>Journal of Chromatographic Science</i> , 2008 , 46, 524-8	1.4	36
268	Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 88, 66-70	3.5	35
267	UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 138, 223-230	3.5	34
266	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3061-6	5.1	34

265	Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 435-44	5.9	33
264	Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. <i>Aids</i> , 2012 , 26, 1529-33	3.5	33
263	Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 280-1	5.1	33
262	UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 129, 535-541	3.5	31
261	Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. <i>Liver International</i> , 2013 , 33, 580-5	7.9	31
260	Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1840-3	5.9	31
259	Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 793-805	6.2	31
258	Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 936, 42-7	3.2	30
257	Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2645-9	5.1	30
256	Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. <i>Journal of Viral Hepatitis</i> , 2013 , 20, e11-9	3.4	30
255	Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 722-8	3.2	30
254	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 134-40	3.8	29
253	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 293-300	1.9	29
252	Inpatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 232-5	3.2	29
251	Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. <i>Clinical Infectious Diseases</i> , 2008 , 46, 146-7	11.6	29
250	Development and validation of UHPLC-MS/MS methods for the quantification of colistin in plasma and dried plasma spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 129, 551-557	3.5	28
249	Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. <i>International Journal of Antimicrobial Agents</i> , 2013 , 41, 590-1	14.3	27
248	Colistin Use in Patients With Reduced Kidney Function. <i>American Journal of Kidney Diseases</i> , 2016 , 68, 296-306	7.4	27

247	An UPLC-MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 107, 512-7	3.5	26
246	Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 850-857	3.4	25
245	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. <i>Antiviral Research</i> , 2013 , 100, 114-9	10.8	25
244	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. <i>Antiviral Research</i> , 2014 , 102, 35-43	10.8	25
243	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , 2011 , 54, 2278-9	11.2	25
242	UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 142, 279-285	3.5	24
241	UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 114, 127-32	3.5	24
240	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 241-5	5.1	24
239	Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 66, 376-80	3.5	24
238	Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 260-3	3.4	23
237	Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. <i>Aids</i> , 2006 , 20, 1977-9	3.5	23
236	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 197-203	3.8	23
235	A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 848, 374-8	3.2	22
234	Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients. <i>Drugs</i> , 2016 , 76, 1161-74	12.1	21
233	UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptopguanosine and 6-methylmercaptapurine riboside in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 98, 271-8	3.5	21
232	A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 78-79, 217-23	3.5	21
231	Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 117-23	14.3	21
230	The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. <i>Journal of Infection</i> , 2014 , 69, 81-7	18.9	20

229	Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 90, 119-26	3.5	20
228	Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 318-27	3.4	19
227	Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 355-369	6.2	19
226	Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. <i>Aids</i> , 2011 , 25, 1437-9	3.5	19
225	A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 86-92	3.2	19
224	Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2535-2543	3.8	19
223	Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. <i>Pharmacogenomics Journal</i> , 2016 , 16, 514-518	3.5	18
222	A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2572-5	5.1	18
221	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 907-10	5.1	18
220	Ceftriaxone bone penetration in patients with septic non-union of the tibia. <i>International Journal of Infectious Diseases</i> , 2011 , 15, e415-21	10.5	18
219	Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. <i>Emerging Infectious Diseases</i> , 2021 , 27,	10.2	18
218	A LC-MS method to quantify tenofovir urinary concentrations in treated patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 114, 8-11	3.5	17
217	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. <i>Antiviral Therapy</i> , 2015 , 20, 335-41	1.6	17
216	Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 431-2	3.1	17
215	First UHPLC-MS/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients. <i>Journal of Mass Spectrometry</i> , 2017 , 52, 187-195	2.2	16
214	Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. <i>Pharmacogenomics Journal</i> , 2015 , 15, 263-71	3.5	16
213	Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 826-827	5.1	16
212	UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 118, 64-69	3.5	16

211	Anidulafungin for <i>Candida glabrata</i> infective endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4552-3	5.9	16
210	Enhancement of calcyclin gene RNA expression in squamous cell carcinoma of the oral mucosa, but not in benign lesions. <i>Journal of Oral Pathology and Medicine</i> , 1997 , 26, 206-10	3.3	16
209	Pharmacogenetics of ribavirin-induced anemia in HCV patients. <i>Pharmacogenomics</i> , 2016 , 17, 925-41	2.6	16
208	Therapeutic drug monitoring of intracellular anti-infective agents. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 101, 183-93	3.5	15
207	Cerebrospinal fluid penetration of tigecycline. <i>Scandinavian Journal of Infectious Diseases</i> , 2014 , 46, 69-72		15
206	Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 224-5	5.1	15
205	Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1066-71	5.9	15
204	Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 409-11	1.6	15
203	SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1035-1043	5.1	15
202	Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1741-1744	5.1	14
201	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3096-9	5.1	14
200	A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 145, 718-724	3.5	14
199	Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 192-200	5.1	14
198	Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz427	1	13
197	Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofy332	1	13
196	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , 2016 , 17, 561-72	2.6	13
195	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 1083-1088	3	13
194	Raltegravir penetration in seminal plasma of healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2744-5	5.9	13

193	LC-MS/MS-Based Quantification of 9 Antiepileptic Drugs From a Dried Sample Spot Device. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 331-339	3.2	13
192	Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. <i>Neurocritical Care</i> , 2019 , 31, 116-124	3.3	13
191	Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015 , 1001, 35-40	3.2	12
190	Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 801-8	3.8	12
189	Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 205.e1-23	9.5	12
188	Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 47-55	7.5	12
187	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 63-9	7.5	12
186	Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4042-7	5.9	12
185	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , 2014 , 109, 7-14	10.8	12
184	Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. <i>Journal of Clinical Virology</i> , 2013 , 56, 167-9	14.5	12
183	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , 2017 , 5,	4.8	12
182	Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1938-9	5.1	12
181	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 767-773	3.5	11
180	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016 , 30, 915-20	3.5	11
179	Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. <i>Journal of Medical Virology</i> , 2014 , 86, 1845-50	19.7	11
178	Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. <i>Malaria Journal</i> , 2011 , 10, 141	3.6	11
177	Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. <i>Aids</i> , 2010 , 24, 931-2	3.5	11
176	An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 110-5	3.2	11

175	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017 , 18, 539-554	2.6	10
174	Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2417-8	5.1	10
173	VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 164-72	1.9	10
172	Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3074-9	5.1	10
171	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018 , 19, 913-925	2.6	10
170	Ultra performance liquid chromatography PDA method for determination of tigecycline in human plasma. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 853-8	3.2	10
169	Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1686-8	5.1	10
168	Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1113-7	5.1	10
167	The and polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017 , 8, 88021-88033	3.3	10
166	Development of Standard Operating Protocols for the Optimization of -Based Formulations for Medical Purposes. <i>Frontiers in Pharmacology</i> , 2019 , 10, 701	5.6	9
165	UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 115, 443-9	3.5	9
164	Effective treatment of hepatitis C virus infection with sofosbuvir and daclatasvir 90 mg in a patient with severe epilepsy on oxcarbazepine. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 347-8	14.3	9
163	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , 2016 , 497, 287-92	6.5	9
162	Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1911-5	5.1	9
161	Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , 2017 , 45, 103-106	5.8	9
160	Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 410-2	3.2	9
159	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. <i>Antiviral Research</i> , 2014 , 106, 105-10	10.8	9
158	Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. <i>Journal of Chemotherapy</i> , 2013 , 25, 376-8	2.3	9

157	Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. <i>Antiviral Therapy</i> , 2011 , 16, 499-504	1.6	9
156	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 874-5	5.1	9
155	A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1356-64	5.1	9
154	A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 90-4	3.2	9
153	Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. <i>Clinical Infectious Diseases</i> , 2007 , 45, 1654-5	11.6	9
152	Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016 , 88, 1953-9	19.7	9
151	Deferasirox pharmacokinetic and toxicity correlation in β -thalassaemia major treatment. <i>Journal of Pharmacy and Pharmacology</i> , 2016 , 68, 1417-1421	4.8	9
150	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , 2018 , 19, 145-165	2.6	9
149	Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 657-61	14.3	8
148	Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105908	14.3	8
147	A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 94, 65-70	3.5	8
146	Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015 , 18, 171-6	3.4	8
145	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 307-8	5.1	8
144	SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1155-60	5.1	8
143	Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1340-5	5.1	8
142	Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplant. <i>American Journal of Transplantation</i> , 2009 , 9, 2429-34	8.7	8
141	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 307-10	1.9	8
140	Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. <i>Antiviral Research</i> , 2016 , 136, 32-36	10.8	8

139	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1155-7	2.8	8
138	Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1167-76	5.5	7
137	Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. <i>Archives of Virology</i> , 2015 , 160, 2009-17	2.6	7
136	Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 615-620	3.5	7
135	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	7
134	Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?. <i>Journal of Hepatology</i> , 2013 , 59, 633-4	13.4	7
133	Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 319-321	5.1	7
132	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1932-4	5.1	7
131	Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine. <i>Aids</i> , 2004 , 18, 577-8	3.5	7
130	Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients. <i>Current HIV Research</i> , 2014 , 12, 339-46	1.3	7
129	Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 165-168	3.2	7
128	Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients. <i>Clinical Infectious Diseases</i> , 2016 , 63, 285-6	11.6	7
127	Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1659-1664	5.1	6
126	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1550-1556	2.9	6
125	Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. <i>Antiviral Research</i> , 2014 , 108, 44-7	10.8	6
124	Influence of ABCB11 and HNF4A genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2846-2849	5.1	6
123	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1524-1530	4.8	6
122	Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. <i>Pharmacogenomics</i> , 2014 , 15, 1281-6	2.6	6

121	Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort. <i>Antiviral Therapy</i> , 2013 , 18, 87-94	1.6	6
120	2002 SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4. <i>Journal of Hepatology</i> , 2010 , 52, S463	13.4	6
119	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 384-7	5.1	6
118	Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. <i>Infection, Genetics and Evolution</i> , 2017 , 53, 195-198	4.5	6
117	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 665-670	3.2	6
116	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 812-815	5.1	6
115	Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 324-7	14.3	6
114	Data on the stability of darunavir/cobicistat suspension after tablet manipulation. <i>Data in Brief</i> , 2020 , 30, 105552	1.2	6
113	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 103-109	6.2	6
112	A Common <i>mdr1</i> Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 602-609	3.2	6
111	Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. <i>Journal of Clinical Virology</i> , 2017 , 87, 30-36	14.5	5
110	Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 784-785	14.3	5
109	Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. <i>Pharmacogenomics</i> , 2017 , 18, 651-661	2.6	5
108	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , 2017 , 18, 865-880	2.6	5
107	Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. <i>Archives of Virology</i> , 2018 , 163, 961-967	2.6	5
106	Development and validation of an HPLC-UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIV-positive patients. <i>Biomedical Chromatography</i> , 2018 , 32, e4274	1.7	5
105	Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1760-6	5.1	5
104	Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. <i>Infection</i> , 2012 , 40, 69-75	5.8	5

103	Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV. <i>IUBMB Life</i> , 2013 , 65, 800-54.7	5	5
102	Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 3163-3166	5.1	5
101	Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage. <i>Antiviral Research</i> , 2015 , 116, 45-7	10.8	5
100	F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy. <i>Digestive and Liver Disease</i> , 2012 , 44, S42	3.3	5
99	Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 604-6	3.2	5
98	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 122-130	5.1	5
97	Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. <i>Scientific Reports</i> , 2020 , 10, 16178	4.9	5
96	Rhino-Orbital-Cerebral Mucormycosis after Allogeneic Hematopoietic Stem Cell Transplantation and Isavuconazole Therapeutic Drug Monitoring during Intestinal Graft versus Host Disease. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019 , 11, e2019061	3.2	5
95	Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. <i>Pharmacogenomics Journal</i> , 2018 , 18, 506-515	3.5	5
94	Deferasirox pharmacokinetic evaluation in β -thalassaemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 525-528	4.8	4
93	The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 965-968	3	4
92	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019 , 11,	6.6	4
91	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1436-9	5.1	4
90	Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 545-9	14.3	4
89	Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 885-9	5.1	4
88	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3655-e3664	5.6	4
87	Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain. <i>International Journal of Clinical Pharmacy</i> , 2016 , 38, 749-51	2.3	4
86	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019 , 19, 417-427	3.5	4

85	Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?. <i>Journal of Global Antimicrobial Resistance</i> , 2020 , 20, 22-27	3.4	4
84	Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. <i>Scientific Reports</i> , 2021 , 11, 443	4.9	4
83	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 17-22	1.9	4
82	Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1146-1148	3.8	3
81	A rapid and robust UHPLC-DAD method for the quantification of amphotericin B in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 138, 142-145	3.5	3
80	Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017 , 42, 621-623	2.2	3
79	Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. <i>Infection, Genetics and Evolution</i> , 2017 , 51, 167-172	4.5	3
78	Antiretroviral concentrations in the presence and absence of valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1969-1971	5.1	3
77	Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. <i>Journal of Hepatology</i> , 2014 , 61, 178-9	13.4	3
76	Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 482-4	5.1	3
75	Determination of Perampanel in Dried Plasma Spots: Applicability to Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 309-314	3.2	3
74	Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021 , 210, 105854	5.1	3
73	Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?. <i>Pharmacogenomics Journal</i> , 2019 , 19, 65-71	3.5	3
72	-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	3
71	Clinical relevance of deferasirox trough levels in β -thalassemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018 , 45, 213-216	3	3
70	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018 , 94, 29-35	1.7	3
69	Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. <i>Infezioni in Medicina</i> , 2014 , 22, 107-11	3.6	3
68	A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected]. <i>Infezioni in Medicina</i> , 2015 , 23, 367-9	3.6	3

67	Pharmacogenomic influence on sepsis outcome in critically ill patients. <i>Infezioni in Medicina</i> , 2017 , 25, 45-49	3.6	3
66	Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 546-548	5.1	2
65	Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients. <i>Infection, Genetics and Evolution</i> , 2018 , 60, 42-47	4.5	2
64	Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1380-1383	3.8	2
63	External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. <i>AAPS Journal</i> , 2013 , 15, 308-15	3.7	2
62	Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B. <i>Antiviral Therapy</i> , 2018 , 23, 373-377	1.6	2
61	Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 695-6	3.2	2
60	Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, e118-9	3.1	2
59	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2020 , 14,	5.2	2
58	Lack of concordance between EMIT assay and LC-MS/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection?. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 187, 113337	3.5	2
57	Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 ,	5.9	2
56	Monoclonal antibodies with subnanomolar affinity to tenofovir for monitoring adherence to antiretroviral therapies: from hapten synthesis to prototype development. <i>Journal of Materials Chemistry B</i> , 2020 , 8, 10439-10449	7.3	2
55	The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 665-676	5.5	2
54	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	2
53	Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous ß-thalassaemia. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 84, 1510-1512	7.5	2
52	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 89-102	6.2	2
51	Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis. <i>European Addiction Research</i> , 2018 , 24, 184-188	4.6	2
50	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	2

49	Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. <i>Digestive and Liver Disease</i> , 2017 , 49, 705-708	3.3	1
48	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. <i>Pharmacogenomics</i> , 2017 , 18, 607-611	2.6	1
47	Novel "Matrix-Corrected Calibration" study for the detection of polyunsaturated fatty acids (PUFAs) in plasma and erythrocytes by means of a gas chromatography-mass spectrometry approach optimized to follow up long-term parental patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 176, 112764	3.5	1
46	Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020 , 45, 405-412	2.7	1
45	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. <i>Hypertension</i> , 2016 , 67, e3-4	8.5	1
44	Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. <i>European Journal of Public Health</i> , 2017 , 27, 938-941	2.1	1
43	Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2586-8	5.1	1
42	No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. <i>Aids</i> , 2014 , 28, 1993-5	3.5	1
41	Is peritoneal fluid a sanctuary site for HIV?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2052-3	5.1	1
40	Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012 , 4, e2012007	3.2	1
39	Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 483-5	5.1	1
38	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). <i>Trials</i> , 2021 , 22, 831	2.8	1
37	Impact of imipenem concentration in lung perfusate and tissue biopsy during clinical ex-vivo lung perfusion of high-risk lung donors. <i>Minerva Anestesiologica</i> , 2020 , 86, 617-626	1.9	1
36	Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma. <i>Separations</i> , 2021 , 8, 189	3.1	1
35	Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. <i>Blood</i> , 2012 , 120, 4903-4903	2.2	1
34	Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients. <i>Data in Brief</i> , 2020 , 33, 106445	1.2	1
33	Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4432-4438	3.8	1
32	Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1

31	The Role of IL28B Genotype in HCV-RNA Baseline Levels. <i>Intervirology</i> , 2016 , 59, 67-68	2.5	1
30	Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir. <i>Aids</i> , 2016 , 30, 1491-3	3.5	1
29	Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 750-4	2.2	1
28	Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 94, 202-204	2.9	1
27	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 199-206	1.9	1
26	Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context. <i>Biomedicines</i> , 2021 , 9,	4.8	1
25	Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. <i>Biomedicines</i> , 2021 , 9,	4.8	1
24	Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 2013 , 45, 882-4		0
23	Calcyclin gene expression modulation by medroxyprogesterone acetate. <i>Biochemical Pharmacology</i> , 1997 , 54, 299-305	6	0
22	L-histidine/medroxyprogesterone acetate interaction modulates human breast cancer cell growth and progesterin receptor expression in vitro. <i>Pharmacological Research</i> , 1997 , 35, 119-22	10.2	0
21	Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?. <i>Clinical Drug Investigation</i> , 2008 , 28, 305-11	3.2	0
20	A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 755184	5.6	0
19	Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients. <i>Frontiers in Pharmacology</i> , 2021 , 12, 750433	5.6	0
18	Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106297	14.3	0
17	Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. <i>Pharmacogenomics</i> , 2018 , 19, 701-707	2.6	0
16	Pharmacokinetics of bictegrovir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 3320-3322	5.1	0
15	A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients.. <i>Irish Journal of Medical Science</i> , 2022 , 1	1.9	0
14	A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy. <i>Phytomedicine</i> , 2022 , 102, 154218	6.5	0

- 13 Pharmacokinetics of high dosage of linezolid in two morbidly obese patients-authors response. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 3169 5.1
- 12 Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C. *Antiviral Therapy*, **2019**, 24, 553-555 1.6
- 11 Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia. *Blood*, **2015**, 126, 4838-4838 2.2
- 10 The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. *Blood*, **2016**, 128, 3951-3951 2.2
- 9 Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. *Frontiers in Pharmacology*, **2021**, 12, 668843 5.6
- 8 Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. *Pharmacology Research and Perspectives*, **2021**, 9, e00811 3.1
- 7 A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4. *Intervirology*, **2016**, 59, 283-284 2.5
- 6 Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all?. *Journal of Viral Hepatitis*, **2016**, 23, 402-3 3.4
- 5 Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. *Therapeutic Drug Monitoring*, **2019**, 41, 254-255 3.2
- 4 Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump. *International Journal of Pharmaceutical Compounding*, **2016**, 20, 343-346 0.2
- 3 Ceftobiprole and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis.. *Journal of Chemotherapy*, **2022**, 1-3 2.3
- 2 The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0013522 5.9
- 1 Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. *Pharmaceuticals*, **2022**, 15, 630 5.2